Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection

Inclusion Criteria

• •Incidence Phase
• •* HIV-1 status unknown at initial screening and no prior human immunodeficiency virus (HIV)-1 testing within the last 3 months.
• •* Sexually active (has had \> 1 vaginal intercourse within the last 3 months) with cisgender male individuals (CGM).
• •Randomized Phase
• •* Negative fourth generation HIV-1 antibody (Ab)/antigen (Ag) test confirmed with central HIV-1 testing.
• •* Estimated glomerular filtration rate (GFR) ≥ 60 mL/min at screening.
• •* Body weight ≥ 35 kg.